CAJ | 학술논문

目的比较分析并探讨长春瑞滨(NVB)联合吉西他滨(GEM)的GN方案与NVB联合顺铂(DDP)的NP方案治疗晚期非小细胞肺癌(NSCLC)的疗效及患者不良反应.方法回顾性分析经组织学证实的56例晚期NSCLC患者,GN组27例:NVB+GEM,每3周1个周期×2～6个周期,NP组29例:NVB+DDP,每3周1个周期×2～6个周期.结果 GN组总有效率37.0%,肿瘤控制率59.3%.中位疾病进展期5.1个月,1年生存率40.7%.其疗效与NP组接近,差异无统计学意义(P＞0.05),但GN组在血红蛋白下降、Ⅱ度以上恶心、呕吐及体力下降三项不良反应方面发生率明显低于NP组,两组之间不良反应统计差异有统计学意义(P＜0.05).结论非铂类GN方案疗效高、毒性低、耐受性好,作为晚期NSCLC患者的一线替代方案值得进一步研究.
목적 비교분석병탐토장춘서빈(NVB)연합길서타빈(GEM)적GN방안여NVB연합순박(DDP)적NP방안치료만기비소세포폐암(NSCLC)적료효급환자불량반응.방법 회고성분석경조직학증실적56례만기NSCLC환자,GN조27례:NVB+GEM,매3주1개주기×2～6개주기,NP조29례:NVB+DDP,매3주1개주기×2～6개주기.결과 GN조총유효솔37.0%,종류공제솔59.3%.중위질병진전기5.1개월,1년생존솔40.7%.기료효여NP조접근,차이무통계학의의(P＞0.05),단GN조재혈홍단백하강、Ⅱ도이상악심、구토급체력하강삼항불량반응방면발생솔명현저우NP조,량조지간불량반응통계차이유통계학의의(P＜0.05).결론 비박류GN방안료효고、독성저、내수성호,작위만기NSCLC환자적일선체대방안치득진일보연구.
Objective To compare and evaluate the clinical efficacy and side effect of vinorelbine plus gemcitabine and vinorelbine plus cisplatin combinations in advanced non-small-cell lung cancer(NSCLC). Methods 56 cases with non-treated advanced NSCLC were unrandomly divided into two groups: the GN group (27patients) treated with vinorelbine plus gemcitabine, the NP group (29 patients) treated with vinorelbine plus cisplatin,1/3 weeks×2～6 cycles. Results For the GN group, the overall response rate was 37.7 %, MTTP was 5.1months,one year survival rate (1-ySR) was 40.7 %. There were no significant difference in the response rates and the survival rates for the GN group compared with the NP group (P ＞0.05); But on the side effect of toxicities, WHO grade anemia and nausea/vomiting and tiredness of the GN group was significantly milder than the NP group (P ＜ 0.05). Conclusion Vinorelbine combined Gemcitabine regimen (GN) is active and well-tolerated. It is worth to investigate GN recommended as the first line chemotherapeutic regimen for the treatment of patients with advanced NSCLC.